Discovery of new targets for rare diseases - developing new therapies to cure ALS

19 June: 13:30 - 14:00

Dr Inez de Greef-van der Sandt, CEO, Treeway & Partner, 3D-PharmXchange, Treeway & 3D-PharmXchange

ABSTRACT

BIOGRAPHY

Inez is a pharmaceutical professional with extensive experience within the pharma and biotech industry. In-depth knowledge of the different elements of drug development and the interfaces between them. As partner and co-founder of 3D-PharmXchange she is responsible for the strategy and management of 3D-PharmXchange. In 2013 she was appointed as CEO for our client Treeway, a biotechnology company with a mission to develop therapies to cure ALS.

Her interests are in the strategic aspects and the valuation of drug and companion diagnostic development projects, as well as the potential for collaboration and synergy in this development space between big pharma and smaller biotech companies. She has a passion for driving results that truly impact critical decisions through leadership and/or participation in multidisciplinary efforts at the interface between science and business.

Prior to founding 3D-PharmXchange, she was Director Clinical Development and Chief Operating Officer of Kinesis Pharma. She also worked for several years as consultant and project manager on clinical and PK-PD projects in several therapeutic areas.

At Tibotec-Virco, she managed the clinical pharmacology program for their successfully approved HIV protease inhibitor Prezistra and follow-up compounds.  At Leiden Advanced Experts on PK and PD (LAP&P) she was responsible for modeling & simulation projects and project management.

Inez studied Medical Biology at the University of Amsterdam, The Netherlands, and obtained her PhD at the department of Pharmacology from the LACDR at Leiden University, The Netherlands. 

COMPANY PROFILE

Treeway is a biotech company with a focus on the development of therapies for Amyotrophic Lateral Sclerosis. ALS is a fatal progressive neurodegenerative disease for which currently no effective treatment is available. Treeway has built a pipeline of two products (TW001 and TW002) and several research lines, including access to the world largest independent large-scale ALS genetic research (Project MinE).
Treeway’s mission is to develop new therapies for patients by patients as soon as possible.New insights, for example coming from Project MinE may in the end result in finding a cure for ALS. Treeway follows a virtual company business approach to limit fixed costs and be very flexible in the need for specific resources to obtain our business goals. For this purpose, Treeway hired 3D-PharmXchange as their drug development partner.